水飞蓟宾磷脂酰胆碱复合物治疗慢性乙型肝炎的疗效观察

目的:观察水飞蓟宾磷脂酰胆碱复合物治疗肝功能异常的慢性乙型肝炎的疗效和安全性.方法:选取80例肝功能异常的慢性乙肝患者,随机分成试验组和对照组各40例.试验组口服水飞蓟宾磷脂酰胆碱复合物,每次120 mg,tid,共12周,对照组口服护肝宁片每次4片,tid,疗程12周;对两组疗效进行比较,评价治疗前后患者临床症状和肝功能与肝纤维化指标的恢复情况,同时记录不良反应.结果:治疗后,试验组和对照组病人的症状均有不同程度改善,其中试验组有乏力和腹胀病人的症状改善率明显高于对照组(P＜0.05).两组患者治疗后的肝功能及血清纤维化指标与治疗前比较均得到显著改善,但两组间比较差异无统计学意义(P＞0.05).试验组总有效率达75%,对照组为70%,两组比较差异无统计学意义(P＞0.05).且都无明显的不良反应.结论:水飞蓟宾磷脂酰胆碱复合物治疗肝功能异常的慢性乙肝患者安全、有效.

Therapeutic effects of silybin-phosphatidylcholine compound on patients with chronic hepatitis B

AIM:To evaluate the efficacy and safety of silybin-phosphatidylcholine compound (SPC) for patients with chronic hepatitis B(CHB).METHODS:Eighty patients with chronic hepatitis B (abnormal ALT level)were randomly divided into two different groups:the patients of trial group(n = 40) were treated with SPC (120 mg,tid) for 12 weeks,and the control group (n = 40)were treated with Chinese herbs compound Huganning pills (4 #,tid) 12 weeks.Before and after treatment,the clinical symptom and the serum parameters of liver function and fibrosis were evaluated for the patients of both groups,and the adverse effects were recorded.RESULTS:After treatment,the clinical symptoms were improved in different degree in the patients of both groups,the improvement rate of the fatigue and belly inflation in trial group were obvious higher than those in control group (P ＜ 0.05).After treatment,both liver function and fibrosis parameters were significantly improved,and there was no significant difference between the two groups.The gross efficacies in trial group and control group were 75%,70%,respectively.No serious adverse events were reported in both groups.CONCLUSION:It has been suggested that SPC has significant therapeutic effects on chronic hepatitis B,and it is safety.